Research Article
BibTex RIS Cite

Colchicine as a potential HDAC inhibitor: comparative binding energies and prospects for cancer therapy repurposing

Year 2024, Volume: 28 Issue: 5, 1812 - 1819, 28.06.2025

Kerem Buran

Abstract

Drug repurposing, also known as drug repositioning or drug reprofiling, is gaining momentum as a strategy to identify novel therapeutic uses for existing drugs outside their original medical indications. This approach leverages the known safety profiles and mechanisms of action of approved medications to expedite the development of treatments for various diseases. Colchicine, an ancient herbal medicine with established anti-inflammatory properties and recognized efficacy in conditions like gout and Familial Mediterranean fever, has garnered interest in its potential applications beyond traditional uses. The discovery of colchicine's binding capacity to microtubules, essential for cellular structure and mitosis, has sparked exploration into its role in cancer therapy. Histone deacetylase inhibitors (HDACs) have also shown promise in cancer research by modulating gene expression through histone and non-histone protein acetylation. While colchicine is not conventionally classified as an HDAC inhibitor, studies suggest its potential impact on HDAC activity. This study aims to investigate the similarities in enzyme binding energies between colchicine and HDAC inhibitors, exploring the potential utility of colchicine as an HDAC inhibitor and introducing a new avenue for cancer treatment. By elucidating the potential therapeutic overlap between colchicine and HDAC inhibitors, this research seeks to advance the field of drug repurposing and provide novel insights into the treatment of cancer and other diseases.

Keywords

Colchicine drug repurposing HDAC docking anticancer

References

  • [1] Sleire L, Førde HE, Netland IA, Leiss L, Skeie BS, Enger PØ. Drug repurposing in cancer. Pharmacol Res. 2017; 124: 74–91. https://doi.org/https://doi.org/10.1016/j.phrs.2017.07.013
  • [2] Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, Doig A, Guilliams T, Latimer J, McNamee C, Norris A, Sanseau P, Cavalla D, Pirmohamed M. Drug repurposing: Progress, challenges and recommendations. Nat Rev Drug Discov. 2018; 18: 41–58. https://doi.org/10.1038/nrd.2018.168
  • [3] Zhang F, He Q, Qin CH, Little PJ, Weng J, Xu S. Therapeutic potential of colchicine in cardiovascular medicine: a pharmacological review. Acta Pharmacol Sin. 2022; 43: 2173–2190. https://doi.org/10.1038/s41401-021-00835-w
  • [4] Imazio M, Nidorf M. Colchicine and the heart. Eur Heart J. 2021; 42: 2745–2760. https://doi.org/10.1093/eurheartj/ehab221
  • [5] Deftereos SG, Beerkens FJ, Shah B, Giannopoulos G, Vrachatis DA, Giotaki SG, Siasos G, Nicolas J, Arnott C, Patel S, Parsons M, Tardif JC, Kovacic JC, Dangas GD. Colchicine in cardiovascular disease: In-depth review. Circulation. 2022; 145: 61–78. https://doi.org/10.1161/CIRCULATIONAHA.121.056171
  • [6] Onódi Z, Koch S, Rubinstein J, Ferdinandy P, Varga Z V. Drug repurposing for cardiovascular diseases: New targets and indications for probenecid. Br J Pharmacol. 2023; 180: 685–700. https://doi.org/https://doi.org/10.1111/bph.16001
  • [7] McLoughlin EC, O'Boyle NM. Correction: McLoughlin EC, O'Boyle NM. Colchicine-binding site ınhibitors from chemistry to clinic: A review. Pharmaceuticals. 2020; 13: 8. Pharmaceuticals (Basel). 2020;13(4):72. https://doi.org/10.3390/ph13040072 Erratum for: Pharmaceuticals (Basel). 2020;13(1):E8. https://doi.org/10.3390/ph13010008.
  • [8] Melesina J, Simoben CV, Praetorius L, Bülbül EF, Robaa D, Sippl W. Strategies to design selective histone deacetylase inhibitors. ChemMedChem. 2021;16:1336–1359. https://doi.org/10.1002/cmdc.202000934
  • [9] Daśko M, de Pascual-Teresa B, Ortín I, Ramos A. HDAC inhibitors: Innovative strategies for their design and applications. Molecules. 2022; 27(3):715.. https://doi.org/10.3390/molecules27030715
  • [10] Liu Y-M, Liou J-P. An updated patent review of histone deacetylase (HDAC) inhibitors in cancer (2020 – present). Expert Opin Ther Pat. 2023; 33: 349–369. https://doi.org/10.1080/13543776.2023.2219393
  • [11] Roy R, Ria T, RoyMahaPatra D, Sk UH. Single inhibitors versus dual ınhibitors: Role of HDAC in cancer. ACS Omega. 2023; 8: 16532–16544. https://doi.org/10.1021/acsomega.3c00222
  • [12] Uba AI, Zengin G. Phenolic compounds as histone deacetylase inhibitors: Binding propensity and interaction insights from molecular docking and dynamics simulations. Amino Acids. 2023; 55: 579–593. https://doi.org/10.1007/s00726-023-03249-6
  • [13] Xiong G, Wu Z, Yi J, Fu L, Yang Z, Hsieh C, Yin M, Zeng X, Wu C, Lu A, Chen X, Hou T, Cao D. ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties. Nucleic Acids Res. 2021; 49: W5–14. https://doi.org/10.1093/nar/gkab255
  • [14] Liu Y, Grimm M, Dai W, Hou M, Xiao Z-X, Cao Y. CB-Dock: A web server for cavity detection-guided protein–ligand blind docking. Acta Pharmacol Sin. 2020; 41: 138–144. https://doi.org/10.1038/s41401-019-0228-6
  • [15] Cao Y, Li L. Improved protein–ligand binding affinity prediction by using a curvature-dependent surface-area model. Bioinformatics. 2014; 30: 1674–1680. https://doi.org/10.1093/bioinformatics/btu104
There are 15 citations in total.

Details

Primary Language English
Subjects Pharmaceutical Chemistry
Journal Section Articles
Authors

Kerem Buran 0000-0002-7783-7533

Publication Date June 28, 2025
Submission Date June 29, 2024
Acceptance Date August 14, 2024
Published in Issue Year 2024 Volume: 28 Issue: 5

Cite

APA Buran, K. (2025). Colchicine as a potential HDAC inhibitor: comparative binding energies and prospects for cancer therapy repurposing. Journal of Research in Pharmacy, 28(5), 1812-1819.
AMA Buran K. Colchicine as a potential HDAC inhibitor: comparative binding energies and prospects for cancer therapy repurposing. J. Res. Pharm. July 2025;28(5):1812-1819.
Chicago Buran, Kerem. “Colchicine As a Potential HDAC Inhibitor: Comparative Binding Energies and Prospects for Cancer Therapy Repurposing”. Journal of Research in Pharmacy 28, no. 5 (July 2025): 1812-19.
EndNote Buran K (July 1, 2025) Colchicine as a potential HDAC inhibitor: comparative binding energies and prospects for cancer therapy repurposing. Journal of Research in Pharmacy 28 5 1812–1819.
IEEE K. Buran, “Colchicine as a potential HDAC inhibitor: comparative binding energies and prospects for cancer therapy repurposing”, J. Res. Pharm., vol. 28, no. 5, pp. 1812–1819, 2025.
ISNAD Buran, Kerem. “Colchicine As a Potential HDAC Inhibitor: Comparative Binding Energies and Prospects for Cancer Therapy Repurposing”. Journal of Research in Pharmacy 28/5 (July 2025), 1812-1819.
JAMA Buran K. Colchicine as a potential HDAC inhibitor: comparative binding energies and prospects for cancer therapy repurposing. J. Res. Pharm. 2025;28:1812–1819.
MLA Buran, Kerem. “Colchicine As a Potential HDAC Inhibitor: Comparative Binding Energies and Prospects for Cancer Therapy Repurposing”. Journal of Research in Pharmacy, vol. 28, no. 5, 2025, pp. 1812-9.
Vancouver Buran K. Colchicine as a potential HDAC inhibitor: comparative binding energies and prospects for cancer therapy repurposing. J. Res. Pharm. 2025;28(5):1812-9.